Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcus Biosciences Inc (NY: RCUS )

14.15 +0.09 (+0.64%)
Official Closing Price Updated: 7:00 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 338,677
Open 14.08
Bid (Size) 13.23 (3)
Ask (Size) 14.50 (3)
Prev. Close 14.06
Today's Range 13.67 - 14.18
52wk Range 12.95 - 36.13
Shares Outstanding 74,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
From laggards to leaders: Small caps on the rise
Despite large-cap dominance, signs suggest a shift to small-cap leadership. Valuations, positive Q3 results, and historical patterns point to potential gains. 
Via MarketBeat

Performance

YTD
-29.95%
-29.95%
1 Month
-5.35%
-5.35%
3 Month
-29.88%
-29.88%
6 Month
-30.16%
-30.16%
1 Year
-50.58%
-50.58%

More News

Read More
Arcus Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
From Arcus Biosciences
Via Business Wire
What 9 Analyst Ratings Have To Say About Arcus Biosciences
Via Benzinga
Arcus Biosciences: Q3 Earnings Insights
Via Benzinga
Expert Ratings for Arcus Biosciences
Via Benzinga
Where Arcus Biosciences Stands With Analysts
Via Benzinga
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity
Via Benzinga
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
From Gilead Sciences, Inc.
Via Business Wire
5 Analysts Have This to Say About Arcus Biosciences
Via Benzinga
Earnings Scheduled For November 7, 2023
Via Benzinga
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences to Present Data from Ongoing EDGE-Gastric Study at ASCO Plenary and to Report Third-Quarter Financial Results on November 7
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Grab Holdings Are Trading Higher By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30%
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback